770671-04-0

Basic information

• Product Name: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-
• Synonyms: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-;1-(3-(4-Methylpiperazin-1-yl)phenyl)guanidine;2-[3-(4-methylpiperazin-1-yl)phenyl]guanidine
• CAS NO: 770671-04-0
• Molecular Formula: C₁₂H₁₉N₅
• Molecular Weight: 233.31276
• Mol File: 770671-04-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-(770671-04-0)
• EPA Substance Registry System: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-(770671-04-0)

Safety Data

• Hazardous Substances Data: 770671-04-0(Hazardous Substances Data)

Usage

General Description

Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-, also known as GMP, is a chemical compound used in the pharmaceutical industry for its potential therapeutic properties. It is a guanidino compound with a piperazine ring and a phenyl group, and its structure suggests potential biological activity. GMP has been investigated for its potential applications in the treatment of various medical conditions, including central nervous system disorders and cancer. Its unique structure and potential pharmacological effects make it a promising candidate for further research and development in the field of medicine and drug discovery.

Upstream product

• 420-04-2 CYANAMID 
• 148546-99-0 3-(4-methylpiperazin-1-yl)aniline 
• 1143571-97-4 (E)-tert-butyl (tert-butoxycarbonylamino)(3-(4-methyl-piperazin-1-yl)-phenylamino)methylenecarbamate 

Downstream Products

• 1142947-79-2 6-amino-5-(2,2-diethoxy-ethyl)-2-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ol 
• 927653-64-3 4-[1-methyl-3-(4-nitro-phenyl)-1H-pyrazol-4-yl]-N-[3-(4-methyl-piperazin-1-yl)phenyl]-pyrimidin-2-amine 

Relevant articles and documents

Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents

A series of 2,4,5-trisubstituted pyrimidines have been synthesised and characterised, which exhibited potent CDK inhibition and anti-proliferative activities. The structure-activity relationship is analysed and a rational for CDK9 selectivity is discussed

PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.